United States
China
Hong Kong SAR ChinaBiotech & Genomic Medicine▲2impact 4
Moderna and Merck's cancer vaccine succeeds in Phase III trial, A-share vaccine stocks hit 20% daily limit
Moderna and Merck announced preliminary positive results from the Phase III clinical trial of their mRNA personalized cancer vaccine, intismeran autogene, igniting the A-share pharmaceutical sector. On the morning of August 20, multiple vaccine stocks including Baike Biotech, Walvax Biotechnology, CanSino Biologics, Kanghua Biologics, Laimei Pharmaceutical, and Novoprotein hit the 20% daily limit, while Hong Kong-listed CanSino Biologics and Everest Medicines surged over 50% intraday. The vaccine, combined with Keytruda, was used as adjuvant therapy in more than 1,100 high-risk melanoma patients after complete surgical resection, achieving key endpoints of recurrence-free survival and reduced risk of distant metastasis. Following the announcement, Moderna's stock price soared nearly 180%, while Merck's rose over 12%.
About megatrends
Biotech & Genomic Medicine › mRNA Platforms ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics ▲Competition
MRNA · Technology · Positive Moderna's mRNA cancer vaccine achieved positive Phase III results, driving stock surge.
MRK · Technology · Positive Merck's cancer vaccine with Moderna succeeded in Phase III trial, boosting its stock.
300142.CS · Demand · Positive A-share vaccine stocks hit 20% daily limit on Moderna/Merck's successful Phase III cancer vaccine trial, boosting sector sentiment.
300841.CS · Demand · Positive A-share vaccine stocks hit 20% daily limit on Moderna/Merck's successful Phase III cancer vaccine trial, boosting sector sentiment.
1952.HK · Demand · Positive Everest Medicines surged over 50% intraday as vaccine sector rallied on the news.
688137.CG · Demand · Positive Novoprotein hit 20% daily limit as vaccine stocks rallied on the trial success.